PHARMAC secures advance purchase agreement for a pre-exposure COVID-19 treatment

PHARMAC

31 March 2022 - PHARMAC has negotiated an agreement with AstraZeneca for its pre-exposure prophylactic COVID-19 treatment, which would be targeted to our most vulnerable New Zealanders. 

Tixagevimab with cilgavimab (supplied under the brand name Evusheld) is PHARMAC’s fourth advance purchase agreement for a COVID-19 treatment, and its first for a pre-exposure prophylactic treatment.

Read PHARMAC press release

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Medicine , New Zealand , Supply , COVID-19